adalimumab-atto
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo
The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Phase 3 results announced for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
FDA approves Priovant’s Lisraya for dermatomyositis
This is the first oral drug treatment for this rare disease in adults
AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
FDA grants Fast Track status for peanut allergy immunotherapy
The treatment uses peptides designed to retrain the immune system to tolerate peanuts
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Cases of skin cancer set to reach 263,000 in 2035 according to new report
The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Teva submits FDA application for paediatric Tourette syndrome therapy
Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years